Drug Combinations
Drug Therapy, Combination
Drug Interactions
Antineoplastic Combined Chemotherapy Protocols
Proguanil
Methenamine
Antimalarials
Dapsone
Artemisinins
Drug Therapy
Atovaquone
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Methylthioinosine
Drug Antagonism
Tropicamide
Cellophane
Sulfamethoxazole
Pyrimethamine
Mefloquine
Drug Resistance
Pharmaceutical Preparations
Inhibitory Concentration 50
Drug Evaluation, Preclinical
Floxuridine
Sulfadoxine
Cisplatin
Molecular Targeted Therapy
Rifampin
Nanoconjugates
Microbial Sensitivity Tests
Xenograft Model Antitumor Assays
Cell Survival
Amikacin
Chloroquine
Phentermine
Fluorouracil
Doxorubicin
Naphthoquinones
Antifungal Agents
Apoptosis
Pyrimidines
Treatment Outcome
Drug-Related Side Effects and Adverse Reactions
Niacinamide
Drug Resistance, Neoplasm
Antitubercular Agents
Plasmodium falciparum
Pharmacology
Drug Administration Schedule
Trimethoprim
Drug Design
Systems Biology
Neoplasms
Amphotericin B
Anti-HIV Agents
Parasitic Sensitivity Tests
Cytarabine
Malaria, Falciparum
Medetomidine
Drug Resistance, Multiple
Paclitaxel
Clinical Trials, Phase I as Topic
Antihypertensive Agents
Clinical Trials as Topic
Mice, SCID
Itraconazole
Triazines
Mice, Nude
Taxoids
Methotrexate
Etoposide
Sirolimus
Models, Biological
Ethambutol
Tumor Cells, Cultured
Malaria
Pyridines
Cell Cycle
Drug Evaluation
Echinocandins
Benzoquinones
Cyclophosphamide
Ketamine
Algorithms
Signal Transduction
Antineoplastic Agents, Alkylating
Reverse Transcriptase Inhibitors
Dacarbazine
Models, Statistical
Tacrolimus
Multiple Myeloma
HIV Infections
Drug Delivery Systems
Antiviral Agents
Disease Models, Animal
Enzyme Inhibitors
Drug Resistance, Microbial
Drug Resistance, Viral
Computational Biology
Fluconazole
Parasitemia
Histone Deacetylase Inhibitors
Cell Death
Camptothecin
Combined Modality Therapy
Indoles
Models, Theoretical
Treatment Failure
Zidovudine
Proto-Oncogene Proteins c-bcl-2
Antineoplastic Agents, Phytogenic
TOR Serine-Threonine Kinases
Ovarian Neoplasms
Leukemia, Myeloid, Acute
HIV-1
Random Allocation
Area Under Curve
Glioblastoma
Brain Neoplasms
Neoplasm Transplantation
Receptor, Epidermal Growth Factor
Pancreatic Neoplasms
Imidazoles
Adrenergic beta-Antagonists
Antibodies, Monoclonal, Humanized
Aspirin
Ethanol
Angiotensin-Converting Enzyme Inhibitors
Immunosuppressive Agents
Survival Analysis
Rats, Sprague-Dawley
DNA Damage
Flow Cytometry
Caspases
Receptor, erbB-2
Cell Division
Infusions, Intravenous
Hypertension
Chromatography, High Pressure Liquid
Blotting, Western
Mutation
Proto-Oncogene Proteins c-akt
Disease-Free Survival
Kidney
Cells, Cultured
Phosphorylation
Survival Rate
Enzyme Activation
Persistent damage to Enterocytozoon bieneusi, with persistent symptomatic relief, after combined furazolidone and albendazole in AIDS patients. (1/7446)
AIM: To investigate morphological changes in Enterocytozoon bieneusi and the duration of symptomatic relief after combination treatment with furazolidone and albendazole in AIDS patients. METHODS: Four severely immunocompromised AIDS patients with symptomatic E bieneusi infection of the gut received an 18 day course of combined furazolidone and albendazole (500 + 800 mg daily). All patients were monitored for parasite shedding in stool by light microscopy at the end of treatment and monthly during follow up. At the end of treatment, duodenal biopsy specimens obtained from three patients were studied by transmission electron microscopy by two pathologists blind to the patients' treatment or clinical outcome. Duodenal biopsy specimens obtained from one of the patients two months after completion of treatment were also studied electronmicroscopically. RESULTS: All patients had long lasting symptomatic relief, with a major decrease--or transient absence--of spore shedding in stools from completion of treatment. After treatment, changes in faecal spores were persistently found by light microscopy in all cases, and there was evidence of both a substantial decrease in the parasite load and ultrastructural damage in the parasite in all biopsy specimens. The treatment was well tolerated, and no patient had clinical or parasitological relapse during follow up (up to 15 months). CONCLUSIONS: The long lasting symptomatic relief observed in all four treated patients correlated with the persistent decrease in parasite load both in tissue and in stool, and with the morphological changes observed in the life cycle of the protozoan. These data suggest that combined treatment with furazolidone and albendazole is active against E bieneusi and may result in lasting remission even in severely immunocompromised patients. (+info)Emergent immunoregulatory properties of combined glucocorticoid and anti-glucocorticoid steroids in a model of tuberculosis. (2/7446)
In Balb/c mice with pulmonary tuberculosis, there is a switch from a protective Th1-dominated cytokine profile to a non-protective profile with a Th2 component. This switch occurs while the adrenals are undergoing marked hyperplasia. Treatment with the anti-glucocorticoid hormones dehydroepiandrosterone or 3 beta, 17 beta-androstenediol, during the period of adrenal hyperplasia, maintains Th1 dominance and is protective. We investigated the effects of these hormones as therapeutic agents by administering them from day 60, when the switch to the non-protective cytokine profile was already well established. Given at this time (day 60), doses that were protective when given early (from day 0) were rapidly fatal. A physiological dose of the glucocorticoid corticosterone was also rapidly fatal. However when the corticosterone and the anti-glucocorticoid (AED or DHEA) were co-administered, there was protection, with restoration of a Th1-dominated cytokine profile, enhanced DTH responses, and enhanced expression of IL-1 alpha and TNF alpha. Therefore this combination of steroids has an emergent property that is quite unlike that of either type of steroid given alone. It may be possible to exploit the ant-inflammatory properties of glucocorticoids while preserving a Th1 bias, by combining glucocorticoids with DHEA or suitable metabolites. (+info)Precocious estrus and reproductive ability induced by PG 600 in prepuberal gilts. (3/7446)
A total of 29 SPF Large White prepuberal gilts (mean age 152 days at treatment) were examined for estrous and ovulatory responses after PG 600 treatment. After treatment, 85.2% of the gilts showed standing estrus within 6 days. Whereas the treatment-to-estrus interval and duration were 3.7 and 1.9 days respectively. As ovulation occurred on Day 5 to 6, appropriate timing of artificial insemination would be about 4 days after treatment. Fertility of gilts revealed to be excellent, giving rise to a high percentage of normal embryos, 85.3%. Meanwhile, development and growth of fetuses were mostly normal. Other reproductive performances recorded were: mean litter size 6.8; mean birth weight 1.26 kg; weaning-to-return estrus interval 5 to 8 days. In conclusion, PG 600 was found to be useful in inducing fertile estrus in prepuberal gilts, a result which will be of interest for commercial pig farms. (+info)Granulocyte/macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation. (4/7446)
Although young mice homozygous for the osteopetrosis (op) mutation usually developed prominent osteopetrosis, its severity was markedly reduced in aged op/op mice. This age-associated reversal of osteopetrosis was accompanied by the expansion of bone marrow cavities and increased numbers of tartrate-resistant acid phosphatase (TRAP)-positive cells and of macrophages in the bone marrow. The TRAP-positive cells were mononuclear and developed ruffled borders and numerous vesicles, vacuoles, and granules. Enzyme-linked immunosorbent assay demonstrated a significant elevation of serum granulocyte/ macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-3 levels in the aged op/op mice. To examine whether GM-CSF and/or IL-3 could correct osteopetrosis in young op/op mice, 5 ng of recombinant murine (rm)GM-CSF and/or 100 ng of rmIL-3 were injected daily into young op/op mice. In these treated young op/op mice, the bone marrow cavities were expanded significantly at 2 weeks after administration, associated with significantly increased numbers of TRAP-positive cells and bone marrow macrophages. TRAP-positive cells increased in number with days after injection. These results suggest that GM-CSF and IL-3 induce the development of osteoclasts to correct osteopetrosis in the op/op mice with aging. (+info)Transforming growth factor-alpha acting at the epidermal growth factor receptor reduces infarct volume after permanent middle cerebral artery occlusion in rats. (5/7446)
Transforming growth factor-alpha (TGF-alpha) is a ligand for the epidermal growth factor (EGF) receptor (EGFR), and is more abundant than EGF in the brain. The authors studied whether administration of exogenous TGF-alpha into the brain can protect neurons against ischemia in a model of permanent middle cerebral artery (MCA) occlusion in the rat, and whether any effect of TGF-alpha was mediated by EGFR by administering 4,5-dianilinophthalimide (DAPH), a protein-tyrosine kinase inhibitor with high selectivity for EGFR. Rats received either TGF-alpha (10 or 25 ng), DAPH (100 ng), DAPH plus TGF-alpha (25 ng), or vehicle in the ipsilateral first ventricle. Drugs were administered twice: 30 minutes before and 30 minutes after MCA occlusion, and infarct volume was evaluated 24 hours later. Transforming growth factor-alpha at the dose of 25 ng caused a statistically significant reduction of infarct volume (60%) in relation to ischemic rats administered vehicle. This reduction was no longer seen when TGF-alpha was administered in combination with DAPH. The present results show that TGF-alpha can protect neurons from ischemic damage, and that this effect is mediated by EGFR. It is suggested that activation of EGFR-mediated intracellular signalling pathways contributes to the survival of neural cells susceptible to ischemic injury. (+info)Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. (6/7446)
Morphine (Mor) tolerance has been attributed to a reduction of opioid-adrenergic antinociceptive synergy at the spinal level. The present experiments tested the interaction of intrathecally (i.t.) administered Mor-clonidine (Clon) combinations in mice made acutely or chronically tolerant to Mor. ICR mice were pretreated with Mor either acutely (40 nmol i.t., 8 h; 100 mg/kg s.c., 4 h) or chronically (3 mg/kg s.c. every 6 h days 1 and 2; 5 mg/kg s.c. every 6 h days 3 and 4). Antinociception was detected via the hot water (52.5 degrees C) tail-flick test. After the tail-flick latencies returned to baseline levels, dose-response curves were generated to Mor, Clon, and Mor-Clon combinations in tolerant and control mice. Development of tolerance was confirmed by significant rightward shifts of the Mor dose-response curves in tolerant mice compared with controls. Isobolographic analysis was conducted; the experimental combined ED50 values were compared statistically against their respective theoretical additive ED50 values. In all Mor-pretreated groups, the combination of Mor and Clon resulted in significant leftward shifts in the dose-response curves compared with those of each agonist administered separately. In all tolerant and control groups, the combination of Mor and Clon produced an ED50 value significantly less than the corresponding theoretical additive ED50 value. Mor and Clon synergized in Mor-tolerant as well as in control mice. Spinally administered adrenergic/opioid synergistic combinations may be effective therapeutic strategies to manage pain in patients apparently tolerant to the analgesic effects of Mor. (+info)Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. (7/7446)
In an effort to improve the therapeutic selectivity of 5-fluorouracil (FUra) against colorectal cancer, S-1, a combination agent including a prodrug of FUra with two modulators, was recently developed by Taiho Pharmaceuticals Co. S-1 is a combination of tegafur (FT), 5-chloro-2,4-hydroxypyridine, and potassium oxonate in the molar ratio of 1.0:0.4:1.0, with the latter two components as inhibitors of dihydropyrimidine dehydrogenase and phosphoribosylpyrophosphate transferase, respectively. In this study, the therapeutic selectivity and efficacy of S-1 (oral) was compared with FT (oral) and FUra (i.v. infusion) in rats bearing advanced colorectal cancer by using clinically relevant schedules. The maximum tolerated doses (MTDs) of S-1, FT, and FUra were 31.5, 200, and 25 mg/kg/d for 7 days and 22.5, 150, and 12.5 mg/kg/d for 28 days, respectively. The therapeutic index of S-1 was 4- to 5-fold higher than that of either FT or FUra. S-1 achieved 100% complete tumor regression (CR) at its MTD in both 7-day and 28-day schedules. Furthermore, the high incidences of stomatitis, alopecia, and diarrhea observed with FUra and FT, were not observed with S-1. In an attempt to understand the basis for the observed superior therapeutic selectivity with S-1, we studied pharmacokinetic analysis of FUra, drug-induced apoptosis, suppression of mitosis, and inhibition of thymidylate synthase (TS) after S-1, FUra, or FT administration. The peak plasma FUra concentrations derived from FUra or S-1 (FT) at comparable MTDs were similar, but the plasma level of FUra was higher with S-1 than with FUra. Induction of high and sustained apoptosis was achieved with S-1. Although the initial level of apoptosis induced by FUra was comparable to S-1, it was not sustained. The sustained level of apoptosis appears to correlate with tumor growth inhibition. Mitotic figures were more greatly suppressed with S-1 treatment than with FUra. Studies on TS inhibition indicated that, although both S-1 and FUra caused a 4- to 6-fold induction of total TS protein, single oral administration of S-1 was superior to 24-h infusion of FUra in suppressing free TS. The data are consistent with the observation that the therapeutic efficacy of S-1 (100% cure) over FUra is associated with high and sustained levels of drug-induced apoptosis, greater suppression of mitosis, and inhibition of free TS in tumor tissues. (+info)Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness. (8/7446)
OBJECTIVE: During prolonged critical illness, nocturnal pulsatile secretion of GH, TSH and prolactin (PRL) is uniformly reduced but remains responsive to the continuous infusion of GH secretagogues and TRH. Whether such (pertinent) secretagogues would synchronize pituitary secretion of GH, TSH and/or PRL is not known. DESIGN AND METHODS: We explored temporal coupling among GH, TSH and PRL release by calculating cross-correlation among GH, TSH and PRL serum concentration profiles in 86 time series obtained from prolonged critically ill patients by nocturnal blood sampling every 20 min for 9 h during 21-h infusions of either placebo (n=22), GHRH (1 microg/kg/h; n=10), GH-releasing peptide-2 (GHRP-2; 1 microg/kg/h; n=28), TRH (1 microg/kg/h; n=8) or combinations of these agonists (n=8). RESULTS: The normal synchrony among GH, TSH and PRL was absent during placebo delivery. Infusion of GHRP-2, but not GHRH or TRH, markedly synchronized serum profiles of GH, TSH and PRL (all P< or =0.007). After addition of GHRH and TRH to the infusion of GHRP-2, only the synchrony between GH and PRL was maintained (P=0.003 for GHRH + GHRP-2 and P=0.006 for TRH + GHRH + GHRP-2), and was more marked than with GHRP-2 infusion alone (P=0.0006 by ANOVA). CONCLUSIONS: The nocturnal GH, TSH and PRL secretory patterns during prolonged critical illness are herewith further characterized to include loss of synchrony among GH, TSH and PRL release. The synchronizing effect of an exogenous GHRP-2 drive, but not of GHRH or TRH, suggests that the presumed endogenous GHRP-like ligand may participate in the orchestration of coordinated anterior pituitary hormone release. (+info)There are several types of drug-related side effects and adverse reactions, including:
1. Common side effects: These are side effects that are commonly experienced by patients taking a particular medication. Examples include nausea, dizziness, and fatigue.
2. Serious side effects: These are side effects that can be severe or life-threatening. Examples include allergic reactions, liver damage, and bone marrow suppression.
3. Adverse events: These are any unwanted or harmful effects that occur during the use of a medication, including side effects and other clinical events such as infections or injuries.
4. Drug interactions: These are interactions between two or more drugs that can cause harmful side effects or reduce the effectiveness of one or both drugs.
5. Side effects caused by drug abuse: These are side effects that occur when a medication is taken in larger-than-recommended doses or in a manner other than as directed. Examples include hallucinations, seizures, and overdose.
It's important to note that not all side effects and adverse reactions are caused by the drug itself. Some may be due to other factors, such as underlying medical conditions, other medications being taken, or environmental factors.
To identify and manage drug-related side effects and adverse reactions, healthcare providers will typically ask patients about any symptoms they are experiencing, perform physical exams, and review the patient's medical history and medication list. In some cases, additional tests may be ordered to help diagnose and manage the problem.
Overall, it's important for patients taking medications to be aware of the potential for side effects and adverse reactions, and to report any symptoms or concerns to their healthcare provider promptly. This can help ensure that any issues are identified and addressed early, minimizing the risk of harm and ensuring that the patient receives the best possible care.
Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.
Types of Neoplasms
There are many different types of neoplasms, including:
1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.
Causes and Risk Factors of Neoplasms
The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:
1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.
Signs and Symptoms of Neoplasms
The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:
1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.
Diagnosis and Treatment of Neoplasms
The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.
The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:
1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.
Prevention of Neoplasms
While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:
1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.
It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.
Falciparum malaria can cause a range of symptoms, including fever, chills, headache, muscle and joint pain, fatigue, nausea, and vomiting. In severe cases, the disease can lead to anemia, organ failure, and death.
Diagnosis of falciparum malaria typically involves a physical examination, medical history, and laboratory tests to detect the presence of parasites in the blood or other bodily fluids. Treatment usually involves the use of antimalarial drugs, such as artemisinin-based combination therapies (ACTs) or quinine, which can effectively cure the disease if administered promptly.
Prevention of falciparum malaria is critical to reducing the risk of infection, and this includes the use of insecticide-treated bed nets, indoor residual spraying (IRS), and preventive medications for travelers to high-risk areas. Eliminating standing water around homes and communities can also help reduce the number of mosquitoes and the spread of the disease.
In summary, falciparum malaria is a severe and life-threatening form of malaria caused by the Plasmodium falciparum parasite, which is responsible for the majority of malaria-related deaths worldwide. Prompt diagnosis and treatment are essential to prevent complications and death from this disease. Prevention measures include the use of bed nets, indoor spraying, and preventive medications, as well as reducing standing water around homes and communities.
There are several different types of malaria, including:
1. Plasmodium falciparum: This is the most severe form of malaria, and it can be fatal if left untreated. It is found in many parts of the world, including Africa, Asia, and Latin America.
2. Plasmodium vivax: This type of malaria is less severe than P. falciparum, but it can still cause serious complications if left untreated. It is found in many parts of the world, including Africa, Asia, and Latin America.
3. Plasmodium ovale: This type of malaria is similar to P. vivax, but it can cause more severe symptoms in some people. It is found primarily in West Africa.
4. Plasmodium malariae: This type of malaria is less common than the other three types, and it tends to cause milder symptoms. It is found primarily in parts of Africa and Asia.
The symptoms of malaria can vary depending on the type of parasite that is causing the infection, but they typically include:
1. Fever
2. Chills
3. Headache
4. Muscle and joint pain
5. Fatigue
6. Nausea and vomiting
7. Diarrhea
8. Anemia (low red blood cell count)
If malaria is not treated promptly, it can lead to more severe complications, such as:
1. Seizures
2. Coma
3. Respiratory failure
4. Kidney failure
5. Liver failure
6. Anemia (low red blood cell count)
Malaria is typically diagnosed through a combination of physical examination, medical history, and laboratory tests, such as blood smears or polymerase chain reaction (PCR) tests. Treatment for malaria typically involves the use of antimalarial drugs, such as chloroquine or artemisinin-based combination therapies. In severe cases, hospitalization may be necessary to manage complications and provide supportive care.
Prevention is an important aspect of managing malaria, and this can include:
1. Using insecticide-treated bed nets
2. Wearing protective clothing and applying insect repellent when outdoors
3. Eliminating standing water around homes and communities to reduce the number of mosquito breeding sites
4. Using indoor residual spraying (IRS) or insecticide-treated wall lining to kill mosquitoes
5. Implementing malaria control measures in areas where malaria is common, such as distribution of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS)
6. Improving access to healthcare services, particularly in rural and remote areas
7. Providing education and awareness about malaria prevention and control
8. Encouraging the use of preventive medications, such as intermittent preventive treatment (IPT) for pregnant women and children under the age of five.
Early diagnosis and prompt treatment are critical in preventing the progression of malaria and reducing the risk of complications and death. In areas where malaria is common, it is essential to have access to reliable diagnostic tools and effective antimalarial drugs.
Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1% of all cancer deaths worldwide. It is more common in older adults, with most patients being diagnosed over the age of 65.
The exact cause of multiple myeloma is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. There are several risk factors that have been associated with an increased risk of developing multiple myeloma, including:
1. Family history: Having a family history of multiple myeloma or other plasma cell disorders increases the risk of developing the disease.
2. Age: The risk of developing multiple myeloma increases with age, with most patients being diagnosed over the age of 65.
3. Race: African Americans are at higher risk of developing multiple myeloma than other races.
4. Obesity: Being overweight or obese may increase the risk of developing multiple myeloma.
5. Exposure to certain chemicals: Exposure to certain chemicals such as pesticides, solvents, and heavy metals has been linked to an increased risk of developing multiple myeloma.
The symptoms of multiple myeloma can vary depending on the severity of the disease and the organs affected. Common symptoms include:
1. Bone pain: Pain in the bones, particularly in the spine, ribs, or long bones, is a common symptom of multiple myeloma.
2. Fatigue: Feeling tired or weak is another common symptom of the disease.
3. Infections: Patients with multiple myeloma may be more susceptible to infections due to the impaired functioning of their immune system.
4. Bone fractures: Weakened bones can lead to an increased risk of fractures, particularly in the spine, hips, or ribs.
5. Kidney problems: Multiple myeloma can cause damage to the kidneys, leading to problems such as kidney failure or proteinuria (excess protein in the urine).
6. Anemia: A low red blood cell count can cause anemia, which can lead to fatigue, weakness, and shortness of breath.
7. Increased calcium levels: High levels of calcium in the blood can cause symptoms such as nausea, vomiting, constipation, and confusion.
8. Neurological problems: Multiple myeloma can cause neurological problems such as headaches, numbness or tingling in the arms and legs, and difficulty with coordination and balance.
The diagnosis of multiple myeloma typically involves a combination of physical examination, medical history, and laboratory tests. These may include:
1. Complete blood count (CBC): A CBC can help identify abnormalities in the numbers and characteristics of different types of blood cells, including red blood cells, white blood cells, and platelets.
2. Serum protein electrophoresis (SPEP): This test measures the levels of different proteins in the blood, including immunoglobulins (antibodies) and abnormal proteins produced by myeloma cells.
3. Urine protein electrophoresis (UPEP): This test measures the levels of different proteins in the urine.
4. Immunofixation: This test is used to identify the type of antibody produced by myeloma cells and to rule out other conditions that may cause similar symptoms.
5. Bone marrow biopsy: A bone marrow biopsy involves removing a sample of tissue from the bone marrow for examination under a microscope. This can help confirm the diagnosis of multiple myeloma and determine the extent of the disease.
6. Imaging tests: Imaging tests such as X-rays, CT scans, or MRI scans may be used to assess the extent of bone damage or other complications of multiple myeloma.
7. Genetic testing: Genetic testing may be used to identify specific genetic abnormalities that are associated with multiple myeloma and to monitor the response of the disease to treatment.
It's important to note that not all patients with MGUS or smoldering myeloma will develop multiple myeloma, and some patients with multiple myeloma may not have any symptoms at all. However, if you are experiencing any of the symptoms listed above or have a family history of multiple myeloma, it's important to talk to your doctor about your risk and any tests that may be appropriate for you.
HIV (human immunodeficiency virus) infection is a condition in which the body is infected with HIV, a type of retrovirus that attacks the body's immune system. HIV infection can lead to AIDS (acquired immunodeficiency syndrome), a condition in which the immune system is severely damaged and the body is unable to fight off infections and diseases.
There are several ways that HIV can be transmitted, including:
1. Sexual contact with an infected person
2. Sharing of needles or other drug paraphernalia with an infected person
3. Mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Blood transfusions ( although this is rare in developed countries due to screening processes)
5. Organ transplantation (again, rare)
The symptoms of HIV infection can be mild at first and may not appear until several years after infection. These symptoms can include:
1. Fever
2. Fatigue
3. Swollen glands in the neck, armpits, and groin
4. Rash
5. Muscle aches and joint pain
6. Night sweats
7. Diarrhea
8. Weight loss
If left untreated, HIV infection can progress to AIDS, which is a life-threatening condition that can cause a wide range of symptoms, including:
1. Opportunistic infections (such as pneumocystis pneumonia)
2. Cancer (such as Kaposi's sarcoma)
3. Wasting syndrome
4. Neurological problems (such as dementia and seizures)
HIV infection is diagnosed through a combination of blood tests and physical examination. Treatment typically involves antiretroviral therapy (ART), which is a combination of medications that work together to suppress the virus and slow the progression of the disease.
Prevention methods for HIV infection include:
1. Safe sex practices, such as using condoms and dental dams
2. Avoiding sharing needles or other drug-injecting equipment
3. Avoiding mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Post-exposure prophylaxis (PEP), which is a short-term treatment that can prevent infection after potential exposure to the virus
5. Pre-exposure prophylaxis (PrEP), which is a daily medication that can prevent infection in people who are at high risk of being exposed to the virus.
It's important to note that HIV infection is manageable with proper treatment and care, and that people living with HIV can lead long and healthy lives. However, it's important to be aware of the risks and take steps to prevent transmission.
1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.
2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.
3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.
4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.
5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.
6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.
7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.
8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.
9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.
10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.
Sources:
1. Dictionary of Medical Microbiology, Second Edition. Edited by A. S. Chakrabarti and S. K. Das. Springer, 2012.
2. Medical Microbiology, Fourth Edition. Edited by P. R. Murray, K. S. N air, and M. J. Laurence. Mosby, 2014.
There are different types of Breast Neoplasms such as:
1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.
2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.
3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.
4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.
5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.
Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.
Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.
It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.
There are several types of lung neoplasms, including:
1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.
Lung diseases can also be classified based on their cause, such as:
1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.
Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.
Benign ovarian neoplasms include:
1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.
Malignant ovarian neoplasms include:
1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.
Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.
AML is a fast-growing and aggressive form of leukemia that can spread to other parts of the body through the bloodstream. It is most commonly seen in adults over the age of 60, but it can also occur in children.
There are several subtypes of AML, including:
1. Acute promyelocytic leukemia (APL): This is a subtype of AML that is characterized by the presence of a specific genetic abnormality called the PML-RARA fusion gene. It is usually responsive to treatment with chemotherapy and has a good prognosis.
2. Acute myeloid leukemia, not otherwise specified (NOS): This is the most common subtype of AML and does not have any specific genetic abnormalities. It can be more difficult to treat and has a poorer prognosis than other subtypes.
3. Chronic myelomonocytic leukemia (CMML): This is a subtype of AML that is characterized by the presence of too many immature white blood cells called monocytes in the blood and bone marrow. It can progress slowly over time and may require ongoing treatment.
4. Juvenile myeloid leukemia (JMML): This is a rare subtype of AML that occurs in children under the age of 18. It is characterized by the presence of too many immature white blood cells called blasts in the blood and bone marrow.
The symptoms of AML can vary depending on the subtype and the severity of the disease, but they may include:
* Fatigue
* Weakness
* Shortness of breath
* Pale skin
* Easy bruising or bleeding
* Swollen lymph nodes, liver, or spleen
* Bone pain
* Headache
* Confusion or seizures
AML is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:
1. Complete blood count (CBC): This test measures the number and types of cells in the blood, including red blood cells, white blood cells, and platelets.
2. Bone marrow biopsy: This test involves removing a small sample of bone marrow tissue from the hipbone or breastbone to examine under a microscope for signs of leukemia cells.
3. Genetic testing: This test can help identify specific genetic abnormalities that are associated with AML.
4. Immunophenotyping: This test uses antibodies to identify the surface proteins on leukemia cells, which can help diagnose the subtype of AML.
5. Cytogenetics: This test involves staining the bone marrow cells with dyes to look for specific changes in the chromosomes that are associated with AML.
Treatment for AML typically involves a combination of chemotherapy, targeted therapy, and in some cases, bone marrow transplantation. The specific treatment plan will depend on the subtype of AML, the patient's age and overall health, and other factors. Some common treatments for AML include:
1. Chemotherapy: This involves using drugs to kill cancer cells. The most commonly used chemotherapy drugs for AML are cytarabine (Ara-C) and anthracyclines such as daunorubicin (DaunoXome) and idarubicin (Idamycin).
2. Targeted therapy: This involves using drugs that specifically target the genetic abnormalities that are causing the cancer. Examples of targeted therapies used for AML include midostaurin (Rydapt) and gilteritinib (Xospata).
3. Bone marrow transplantation: This involves replacing the diseased bone marrow with healthy bone marrow from a donor. This is typically done after high-dose chemotherapy to destroy the cancer cells.
4. Supportive care: This includes treatments to manage symptoms and side effects of the disease and its treatment, such as anemia, infection, and bleeding. Examples of supportive care for AML include blood transfusions, antibiotics, and platelet transfusions.
5. Clinical trials: These are research studies that involve testing new treatments for AML. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available.
It's important to note that the treatment plan for AML is highly individualized, and the specific treatments used will depend on the patient's age, overall health, and other factors. Patients should work closely with their healthcare team to determine the best course of treatment for their specific needs.
Glioblastomas are highly malignant tumors that can grow rapidly and infiltrate surrounding brain tissue, making them difficult to remove surgically. They often recur after treatment and are usually fatal within a few years of diagnosis.
The symptoms of glioblastoma can vary depending on the location and size of the tumor but may include headaches, seizures, weakness or numbness in the arms or legs, and changes in personality, memory or cognitive function.
Glioblastomas are diagnosed through a combination of imaging tests such as CT or MRI scans, and a biopsy to confirm the presence of cancerous cells. Treatment typically involves surgery to remove as much of the tumor as possible, followed by radiation therapy and chemotherapy to slow the growth of any remaining cancerous cells.
Prognosis for glioblastoma is generally poor, with a five-year survival rate of around 5% for newly diagnosed patients. However, the prognosis can vary depending on factors such as the location and size of the tumor, the patient's age and overall health, and the effectiveness of treatment.
Brain neoplasms can arise from various types of cells in the brain, including glial cells (such as astrocytes and oligodendrocytes), neurons, and vascular tissues. The symptoms of brain neoplasms vary depending on their size, location, and type, but may include headaches, seizures, weakness or numbness in the limbs, and changes in personality or cognitive function.
There are several different types of brain neoplasms, including:
1. Meningiomas: These are benign tumors that arise from the meninges, the thin layers of tissue that cover the brain and spinal cord.
2. Gliomas: These are malignant tumors that arise from glial cells in the brain. The most common type of glioma is a glioblastoma, which is aggressive and hard to treat.
3. Pineal parenchymal tumors: These are rare tumors that arise in the pineal gland, a small endocrine gland in the brain.
4. Craniopharyngiomas: These are benign tumors that arise from the epithelial cells of the pituitary gland and the hypothalamus.
5. Medulloblastomas: These are malignant tumors that arise in the cerebellum, specifically in the medulla oblongata. They are most common in children.
6. Acoustic neurinomas: These are benign tumors that arise on the nerve that connects the inner ear to the brain.
7. Oligodendrogliomas: These are malignant tumors that arise from oligodendrocytes, the cells that produce the fatty substance called myelin that insulates nerve fibers.
8. Lymphomas: These are cancers of the immune system that can arise in the brain and spinal cord. The most common type of lymphoma in the CNS is primary central nervous system (CNS) lymphoma, which is usually a type of B-cell non-Hodgkin lymphoma.
9. Metastatic tumors: These are tumors that have spread to the brain from another part of the body. The most common types of metastatic tumors in the CNS are breast cancer, lung cancer, and melanoma.
These are just a few examples of the many types of brain and spinal cord tumors that can occur. Each type of tumor has its own unique characteristics, such as its location, size, growth rate, and biological behavior. These factors can help doctors determine the best course of treatment for each patient.
Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.
Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.
Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.
The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.
Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.
There are two types of hypertension:
1. Primary Hypertension: This type of hypertension has no identifiable cause and is also known as essential hypertension. It accounts for about 90% of all cases of hypertension.
2. Secondary Hypertension: This type of hypertension is caused by an underlying medical condition or medication. It accounts for about 10% of all cases of hypertension.
Some common causes of secondary hypertension include:
* Kidney disease
* Adrenal gland disorders
* Hormonal imbalances
* Certain medications
* Sleep apnea
* Cocaine use
There are also several risk factors for hypertension, including:
* Age (the risk increases with age)
* Family history of hypertension
* Obesity
* Lack of exercise
* High sodium intake
* Low potassium intake
* Stress
Hypertension is often asymptomatic, and it can cause damage to the blood vessels and organs over time. Some potential complications of hypertension include:
* Heart disease (e.g., heart attacks, heart failure)
* Stroke
* Kidney disease (e.g., chronic kidney disease, end-stage renal disease)
* Vision loss (e.g., retinopathy)
* Peripheral artery disease
Hypertension is typically diagnosed through blood pressure readings taken over a period of time. Treatment for hypertension may include lifestyle changes (e.g., diet, exercise, stress management), medications, or a combination of both. The goal of treatment is to reduce the risk of complications and improve quality of life.
Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.
In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.
Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:
1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)
The symptoms of adenocarcinoma depend on the location of the cancer and can include:
1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)
The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.
Treatment options for adenocarcinoma depend on the location of the cancer and can include:
1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.
The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.
Drug combination
Combination drug
Combination therapy
List of antiretroviral fixed-dose combinations
Oleandomycin
Combination antibiotic
Folate
Estradiol benzoate
Combined drug intoxication
Safe Medical Device Amendments of 1990
Codeine
Dicloxacillin
Antimalarial medication
Amoxicillin
Acarbose
Joep Lange
Secret combination (Latter Day Saints)
Clonal hypereosinophilia
Cordyceps gunnii
Vanillin
Gerald Loeb Award winners for Investigative
Biosimilar
Additive effect
Lenalidomide
Synergy
VAMP regimen
Estradiol enantate
Lenvatinib
Eddie Hill
CYP2C19
Ernst Home Centers
Uridine monophosphate synthase
Beaver dam
Hemoencephalography
One Life to Live storylines (1968-1979)
Uncertainty quantification
Fifth Street Historic District
List of DuPont Experimental Station inventions
Cervical cancer
83rd Academy Awards
Scuba set
Veterans benefits for post-traumatic stress disorder in the United States
Blackburn Buccaneer
Job interview
GeoVax
Michael Morales
ATC code M01
Drum roll
Latua
Multiple system atrophy
Bauke Mollema
Rocks (Aerosmith album)
Bucladesine
Heerfordt syndrome
September 1968
Indinavir
Childbirth
Canada Labour Code
Pre-exposure prophylaxis
Troll (Dungeons & Dragons)
Newer Drug Combinations Offer Hope to Those With Mantle Cell Lymphoma
Belladonna Alkaloid Combinations and Phenobarbital: MedlinePlus Drug Information
Yale Cancer Center Study Shows New Drug Combinations Improve Outcomes for Patients with Advanced Lung Cancer
Drug-device combination products under MDR Article 117 | India
Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an...
Current Recommended Treatment against Whipworm Shows Better Results than New Drug Combination
Stabilised combination of drugs comprising naloxone and an opioid analgesic - Patent EP-0913152-B1 - PubChem
Lamivudine : impressive benefits in combination with zidovudine : reports on individual drugs
FDA Issues Warning for Combination Drugs with Acetaminophen - Strom Law Firm
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis - Volume...
Combinations of Anti Malaria Drugs - Malaria Site
Preclinical and clinical investigations of an anti-inflammatory, antipyretic and analgesic drug combination in various animal...
X275 Standout Kenny Hubbard Sounds Off On New ProCharger Combination - Drag Illustrated | Drag Racing News, Opinion, Interviews...
PhD student in network pharmacology modeling of drug combinations (ERC funding)
Personalized Drug Combinations - CancerHacker Lab
View source for Drug combinations - TripSit wiki
5th Drug-Device Combinations & Sustainability Conference | Vonlanthen
Dual-antibody combination therapy produces three to seven months of viral suppression without pills | aidsmap
Nutrients | Free Full-Text | Towards an Integrative Understanding of tRNA Aminoacylation-Diet-Host-Gut Microbiome Interactions...
SAXagliptin Monograph for Professionals - Drugs.com
FDA Approves New Combination Alzheimer's Drug - Psychiatry Advisor
DEA Warns Americans of Drug Combination Deadlier Than Fentanyl
DEA Warns Americans of Drug Combination Deadlier Than Fentanyl
Study finds doctors prescribing untested drug combinations with high addiction potential - learnteethwhitening.com
HHSC to Revise Opiate/Benzodiazepine/Muscle Relaxant Combinations Prior Authorization | Vendor Drug Program
Drostanolone Enanthate: features of the drug, combination - Philippine Red Cross
Dolutegravir and Its Combination Drug Market (Updated Research) | Reports Insights
Combination Vaccines for Childhood Immunization
Antibiotics in the clinical pipeline in 2011 | The Journal of Antibiotics
DNA Replication News, Research - Page 20
Sulfadoxine-Pyrimethamine1
- Chloroquine, quinine and sulfadoxine/pyrimethamine were the most available and prescribed antimalarial drugs in all 60 pharmacies (government and private) in the city. (who.int)
Regimens1
- New antimalarial regimens are, therefore, urgently needed and antimalarial combination chemotherapy is widely advocated. (malariasite.com)
Chemotherapy3
- Currently, first-line treatment of mantle cell lymphoma includes combination chemotherapy with the monoclonal antibody Ritxuan (rituximab), followed by autologous stem cell transplantation - using stem cells from the person being treated. (curetoday.com)
- The main strategy to eliminate soil-transmitted helminths is preventive chemotherapy in the form of mass drug administration. (swisstph.ch)
- Preventive chemotherapy in human helminthiasis : coordinated use of anthelminthic drugs in control interventions : a manual for health professionals and programme managers. (who.int)
Antimalarial drugs3
- Combination therapy with antimalarial drugs is the simultaneous use of two or more blood schizontocidal drugs with independent modes of action and different biochemical targets in the parasite. (malariasite.com)
- This study was done to evaluate the availability and prescribing of antimalarial drugs in Al-Mukalla city, based on the treatment guidelines of the National Malaria Control Programme (NMCP). (who.int)
- More efforts are needed to educate physicians about the NMCP treatment guidelines and to deter pharmacies from random selling of antimalarial drugs. (who.int)
Therapy13
- The bigger question will be whether combination therapy or sequential therapy is better in the long run. (curetoday.com)
- Also of interest is the use of chimeric antigen receptor (CAR)-T cell therapy, for which treatments have been approved by the Food and Drug Administration for the treatment of certain blood cancers, but how it could work for patients with mantle cell lymphoma is still being investigated. (curetoday.com)
- COAST is an open label, randomized, phase 2 trial that studied at adjuvant therapy with durvalumab alone or in combination with oleclumab or monalizumab in patients with locally advanced, unresectable, stage III NSCLC. (ynhh.org)
- Antimalarial combinations can increase efficacy, shorten duration of treatment (and hence increase compliance), and decrease the risk of resistant parasites arising through mutation during therapy. (malariasite.com)
- The concept of combination therapy is based on the synergistic or additive potential of two or more drugs, to improve therapeutic efficacy and also delay the development of resistance to the individual components of the combination. (malariasite.com)
- In patients with metformin contraindications or intolerance (e.g., risk of lactic acidosis, GI intolerance) or in selected other patients, some experts suggest that initial therapy with a drug from another class of antidiabetic agents (e.g., a glucagon-like peptide-1 [GLP-1] receptor agonist, sodium-glucose cotransporter 2 [SGLT2] inhibitor, DPP-4 inhibitor, sulfonylurea, thiazolidinedione, basal insulin) may be acceptable based on patient factors. (drugs.com)
- In such patients with metformin intolerance, some experts suggest initiation of therapy with 2 drugs from other antidiabetic drug classes with complementary mechanisms of action. (drugs.com)
- Consider early initiation of combination therapy for the treatment of type 2 diabetes mellitus to extend the time to treatment failure and more rapidly attain glycemic goals. (drugs.com)
- For patients with inadequate glycemic control on metformin monotherapy, consider patient comorbidities (e.g., atherosclerotic cardiovascular disease [ASCVD], established kidney disease, heart failure), hypoglycemia risk, impact on weight, cost, risk of adverse effects, and patient preferences when selecting additional antidiabetic agents for combination therapy. (drugs.com)
- DPP-4 inhibitors recommended by some experts as one of several classes of drugs for use in combination therapy, particularly in patients with both postprandial and fasting plasma glucose elevations. (drugs.com)
- The paper, "Medical use and combination drug therapy among US adult users of central nervous system stimulants: a cross-sectional analysis," published in BMJ Open , examined patterns of medical amphetamine and methylphenidate stimulant drug use, both substances considered to have a high potential for psychological or physical addiction. (learnteethwhitening.com)
- Longer courses of masteron enanthate, despite all the safety and softness of the drug, still require post-course therapy with Clomid to normalize hormonal levels. (redcrosslaunion.org.ph)
- Although the drugs did not significantly affect the control of blood glucose levels by glyburide, precautions must be taken when the need to co administer these drugs arises especially in a prolonged therapy situation. (who.int)
Synergistic1
- We are developing network pharmacology modelling methods, aiming at a systems-level understanding of how cancer cells can be inhibited by synergistic drug combinations through multi-target perturbations. (bioconductor.org)
Overdose13
- According to the National Institutes of Health, acetaminophen overdose is one of the most common drug poisonings worldwide. (stromlaw.com)
- In recent years, reports about Tylenol and combination drugs that contain acetaminophen - from over-the-counter cough syrup to prescription painkillers - suggest that acetaminophen overdose can occur easily and accidentally. (stromlaw.com)
- These data can be used in combination with nonfatal drug overdose data from the CDC's Drug Overdose Surveillance and Epidemiology ( DOSE ) system to improve understanding of drug use patterns in nonfatal overdoses. (cdc.gov)
- In study sites, blood specimens from patients who experienced a suspected opioid-involved overdose tested positive for fentanyl and fentanyl analogs (78%) of the time , more often than any other drug class. (cdc.gov)
- This underscores the possible risks of non-medical guideline use, noting the issues that warranted the classification of these drugs as having a high potential for psychological or physical dependence and their prominent appearance in toxicology drug rankings of fatal overdose cases. (learnteethwhitening.com)
- Tell your doctor if you or anyone in your family drinks or has ever drunk large amounts of alcohol, uses or has ever used street drugs, or has overused prescription medications, or has had an overdose or if you have or have ever had depression or another mental illness. (medlineplus.gov)
- She previously led CDC's prescription drug overdose team and served as advisor to New York City's Health Commissioner. (cdc.gov)
- But unlike older adults, whose rates continued to increase, teenagers actually had a decline in drug overdose death rates through 2014, before an upturn in 2015. (cdc.gov)
- There are many public health initiatives to combat the rising drug overdose death rates. (cdc.gov)
- The continued rise in drug overdose deaths involving heroin and synthetic opioids from 2014 to 2015 contributed to the uptick between those years. (cdc.gov)
- By gender, the drug overdose death rate for males was higher for females for every year of the 1999-2015 period and was 70% higher in 2015. (cdc.gov)
- While males had a greater increase in drug overdose death rates than females between 1999 and the mid-2000s, they also declined by about a third between 2007 and 2014 before increasing again. (cdc.gov)
- As for the population at large, the majority of drug overdose deaths involve opioids. (cdc.gov)
Efficacy4
- Combination therapies gained increasing attention in the past years as a helminth control strategy to enhance efficacy and slow down drug resistance development. (swisstph.ch)
- The aim of our study was to assess the efficacy and safety of a new treatment combination, moxidectin and albendazole compared with ivermectin and albendazole against Trichuris trichiura ," said Sophie Welsche, recent PhD graduate at Swiss TPH. (swisstph.ch)
- Non-steroidal anti-inflammatory drugs ( NSAIDs ), intravenous fluid, pancreatic stents , or combinations of these have been evaluated in randomised controlled trials (RCTs) for the prevention of post- endoscopic retrograde cholangiopancreatography ( ERCP ) pancreatitis , but the comparative efficacy of these treatments remains unclear. (bvsalud.org)
- We searched PubMed , Embase, and the Cochrane Central Register from inception to Nov 15, 2020, for full-text RCTs that evaluated the efficacy of NSAIDs , pancreatic stents , intravenous fluids, or combinations of these for post- ERCP pancreatitis prevention in adult ( aged ≥18 years) patients undergoing ERCP . (bvsalud.org)
Opioid5
- Updates to the IR opioids state that these drugs should not be used for an extended period unless the pain remains severe enough to require an opioid pain medicine and alternative treatment options are insufficient, and that many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine. (medlineplus.gov)
- Updates to the ER/LA opioids recommend that these drugs be reserved for severe and persistent pain requiring an extended period of treatment with a daily opioid pain medicine and for which alternative treatment options are inadequate. (medlineplus.gov)
- And describe the role of patient beliefs and expectations and value of exercise, education, and non-opioid drug treatments and the management of muscular skeletal pain complaints. (cdc.gov)
- When we examined the specific type of opioid involved, heroin is the leading drug involved and rose fairly steadily throughout the study period. (cdc.gov)
- Synthetic opioids (including fentanyl) were lower than other opioid drugs through the early years of the period, but then doubled between 2014 and 2015. (cdc.gov)
Monoclonal antibody1
- Results show oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with durvalumab improved progression-free survival. (ynhh.org)
Substances7
- BSI has a dedicated Medicinal and Biologics team, which provides guidance on drug-device combination products, conformity assessments of medical devices with ancillary medicinal substances (MDR Rule 14), and substance-based medical devices (MDR Rule 21). (bsigroup.com)
- Select "Common Two Substance Combinations" or "Common Three Substance Combinations" to see the substances found in combination most often. (cdc.gov)
- The term "substances" refers to drugs, adulterants, and contaminants. (cdc.gov)
- Additionally, other substances are potentially present alongside the listed combinations. (cdc.gov)
- Adulterants are additives that increase the bulk-volume of the combined substances, or are physical, chemical, biological, or other substances that are chemically created in a lab with intent to "mimic" (or have similar effects of) another drug, such as marijuana, cocaine, or morphine. (cdc.gov)
- In just one year, over 100,000 Americans died from drug poisoning, and over half of those involved fentanyl or similar substances. (womiowensboro.com)
- They found widespread combination prescribing of drugs classified as Schedule II controlled substances with a high potential for psychological or physical dependence and with limited combined clinical trial testing. (learnteethwhitening.com)
20203
- Recent study on the Dolutegravir and Its Combination Drug Market comprises precise research on quantitative and qualitative aspects to examine the key drivers, opportunities, and threats in the overall development of the Dolutegravir and Its Combination Drug Market on the global scale for the forecast period 2020 - 2025. (reportsinsights.com)
- What is the estimated growth rate and Market share and size of the Dolutegravir and Its Combination Drug Market for the forecast period 2020 - 2025? (reportsinsights.com)
- What are the driving forces in the Dolutegravir and Its Combination Drug Market for the forecast period 2020 - 2025? (reportsinsights.com)
Search3
- Results of search for 'su:{Drug combinations. (who.int)
- Drugs that were found in the 2015 NAMCS and 2015 NHAMCS Emergency Department public use files will show up with an estimate in the search results. (cdc.gov)
- Fill out the form below to search the database for a list of drugs matching your search criteria. (cdc.gov)
20191
- He saw the possibilities on the dyno and everything pointed going in that direction, much to the delight of ProCharger, which has quickly become a prominent player in the drag radial ranks in 2019. (dragillustrated.com)
Naloxone1
- Still, experts always recommend administering naloxone if someone might be suffering from drug poisoning. (womiowensboro.com)
Antibiotics1
- Dietary supplements, antibiotics and certain drugs increase tryptamine content in vivo. (mdpi.com)
Toxicology1
- pharmacological effects of these drugs in animal house of the Department of the patient (7) and may affect the Pharmacology and Toxicology, pharmacokinetics of such drugs (8). (who.int)
Potentially2
- It's another decided advantage of the ProCharger combination, which potentially offers the advantage of quicker runs with less parts damage. (dragillustrated.com)
- The Quantitative Systems Pharmacology research group led by Dr. Jing Tang focuses on developing mathematical and informatics tools to tackle biomedical questions that may potentially lead to breakthroughs in drug discovery. (bioconductor.org)
20172
- In 2017, WHO recommended the combination of ivermectin and albendazole as a treatment against soil-transmitted helminths. (swisstph.ch)
- The PhD student will be involved in the ERC funded project DrugComb (2017-2022) in the field of cancer drug discovery research. (bioconductor.org)
Sequential1
- The total effect of artemisinin combinations (which can be simultaneous or sequential) is to reduce the chance of parasite recrudescence, reduce the within-patient selection pressure, and prevent transmission. (malariasite.com)
Therapies1
- A Major Transition in Malaria Treatment: The Adoption and Deployment of Artemisinin-Based Combination Therapies. (malariasite.com)
Resistance4
- These findings support further evaluation of these drug combinations and have helped us better understand the important challenges of sensitivity and resistance to immunotherapy," said Herbst. (ynhh.org)
- Moxidectin is a particularly interesting candidate because the neglected tropical disease community has voiced concerns regarding potential resistance against ivermectin because of its long history of use in mass drug administration programmes against filarial diseases," explained Emmanuel Mrimi, PhD candidate at Swiss TPH. (swisstph.ch)
- Multidrug resistance has been reported from most parts of the world and as a result, monotherapy or some of the available combination chemotherapies for malaria are either ineffective or less effective. (malariasite.com)
- Artemisinin based combinations are known to improve cure rates, reduce the development of resistance and they might decrease transmission of drug-resistant parasites. (malariasite.com)
Guidance1
- The changes are being made to provide additional guidance for safe use of these drugs while also recognizing the important benefits when used appropriately. (medlineplus.gov)
Treatments2
- MDR TB and XDR TB treatments are of long duration, expensive, and complicated by a high rate of adverse events, making determining an effective drug regimen often difficult, considering that a minimum of 4 active drugs are required according to WHO recommendations ( 1 - 4 ). (cdc.gov)
- Where clinical trials normally inform clinical treatments, the prescribing of multi-combination drug cocktails has yet to go through that process. (learnteethwhitening.com)
Nonprescription1
- The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drugs products available in the U.S. drug market. (cdc.gov)
Inhibitors2
- In several clinical trials, researchers are also looking at how the combination of Venclexta with BTK inhibitors could help improve survival. (curetoday.com)
- Antitubercular event may occur with other drugs within the irrespective of the types of tyrosine kinase inhibitors agents antitubercular agents. (who.int)
Doses3
- In the dose-escalation phase, escalating doses of etrumadenant in combination with zimberelimab will be assessed in participants with advanced malignancies. (clinicaltrials.gov)
- Etrumadenant RP2D will be determined in this part with escalating doses of oral etrumadenant in combination with a fixed dose of IV zimberelimab. (clinicaltrials.gov)
- Sur 42 prescriptions analysées, 54,2 % n'étaient pas conformes aux directives thérapeutiques du Programme en termes de doses et de durée du traitement. (who.int)
Occur3
- Although these drugs are increasingly used in combination in complicated cases ( 8 - 11 ), public health officials are concerned that the co-administration of bedaquiline and delamanid could increase the occurrence of adverse events, particularly for QT prolongation, which might occur more often when these drugs are combined with other TB drugs that prolong the QT interval (i.e., fluoroquinolones and clofazimine). (cdc.gov)
- For the database, this can occur when a drug that was not previously assigned a code by the Multum classification is added to that classification and its DRUGID value in the ACDD is then changed to reflect the new Multum designation. (cdc.gov)
- Drugs showing up without an estimate are in the database but did not occur in the 2015 data. (cdc.gov)
Researchers3
- For instance, at the Medical College of Wisconsin, researchers are examining the drug with Imbruvica in patients with relapsed/refractory mantle cell lymphoma. (curetoday.com)
- New Haven, CT - New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC). (ynhh.org)
- Swiss TPH researchers tested two different drug combinations against the parasitic worm Trichuris trichiura on Pemba Island, Tanzania. (swisstph.ch)
Opioids2
- While we do not know the exact reason for the decline, we know the specific drugs that were involved-opioids, cocaine, and benzodiazepines. (cdc.gov)
- For the opioids, it was the frequently prescribed drugs-methadone and natural and semisynthetic (oxycodone, morphine) that had declines for teens since the mid 2000s. (cdc.gov)
Antibody1
- This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies. (clinicaltrials.gov)
Duration2
- With reasonable dosages and the correct duration of cycles, the drug is practically harmless and does not affect internal organs. (redcrosslaunion.org.ph)
- Of 42 prescriptions analysed, 54.2% did not comply with NMCP guidelines on appropriate dose and duration, especially those prescribed by GPs: 16.7% contained more than 1 antimalarial drug. (who.int)
Fentanyl4
- Many times the fentanyl sold by drug dealers is combined with another drug. (womiowensboro.com)
- The U.S. Drug Enforcement Administration is warning the American public of a sharp increase in the trafficking of fentanyl mixed with xylazine. (womiowensboro.com)
- Xylazine is making the deadliest drug threat our country has ever faced, fentanyl, even deadlier," said Administrator Milgram. (womiowensboro.com)
- Xylazine and fentanyl drug mixtures place users at a higher risk of suffering fatal drug poisoning. (womiowensboro.com)
Clinical trials1
- While there have been clinical trials for each drug, none have been conducted on taking three or four at the same time. (learnteethwhitening.com)
Therapeutic4
- up to 4 therapeutic classes can be assigned per drug in NAMCS and NHAMCS. (cdc.gov)
- For example, a drug that was assigned to only a second-level therapeutic category in one year may now be assigned to a new third-level category. (cdc.gov)
- If a data user is looking for drugs over time, it is important to also check that drug's identifying information as well as Multum's therapeutic category structure in the public use file documentation for the earlier years, in order to ensure that the correct codes are being selected. (cdc.gov)
- When selecting drug therapeutic categories, please note that not all therapeutic categories have second or third levels in the classification scheme. (cdc.gov)
Interactions1
- This metabolic disease administered and monitored may lead to affects diverse organs of the body adverse drug interactions. (who.int)
Food4
- If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online ( http://www.fda.gov/Safety/MedWatch ) or by phone (1-800-332-1088). (medlineplus.gov)
- Actavis and Adamas Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. (psychiatryadvisor.com)
- Xylazine, also known as "Tranq," is a powerful sedative that the U.S. Food and Drug Administration has approved for veterinary use. (womiowensboro.com)
- Beginning with the 2006 survey year, every drug reported in the National Ambulatory Medical Care Survey and National Hospital Medical Care Survey is assigned characteristics, during data processing, based on the Lexicon Plus®, a proprietary database of Cerner Multum, Inc. (The previous Ambulatory Care Drug Database , used prior to the 2006 survey year data, was based on the Food and Drug Administration's National Drug Code Directory). (cdc.gov)
Quantitative1
- Such network models should also include the cancer signalling pathways to elucidate the mechanisms of action, by which a quantitative prediction of a multi-targeted drug or drug combination can be made and tested in follow-up biological experiments. (bioconductor.org)
Improve1
- Used in fixed combination with dapagliflozin (Qtern ) or with dapagliflozin and extended-release metformin hydrochloride (Qternmet XR) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. (drugs.com)
Study4
- Attendees will also have the opportunity to learn about best practices and innovative solutions for making combination products more sustainable, including a case study on a pre-filled autoinjector. (vonlanthenevents.com)
- The Center for Drug Safety and Effectiveness at Johns Hopkins University has led a study into prescription drug use of multiple concurrent central nervous system (CNS)-active drugs. (learnteethwhitening.com)
- It might not even be possible to perform a study with some of the drug combinations due to patient safety and ethical concerns under good clinical practice guidelines. (learnteethwhitening.com)
- The study identified patients who may be getting stimulants or other psychiatric drugs as part of a prescribing cascade. (learnteethwhitening.com)
Findings1
- Findings show that a new treatment combination (moxidectin and albendazole) is inferior compared to the current recommended treatment combination (ivermectin and albendazole). (swisstph.ch)
Data5
- We definitely need more data with that particular combination, but it looked interesting. (curetoday.com)
- After a follow-up of 11.5 months, the data revealed durvalumab in combination with oleclumab reduced the risk of disease progression or death by 56%, and in combination with monalizumab by 35%, when compared to durvalumab alone. (ynhh.org)
- The models shall integrate genotypic, phenotypic and clinical data of cancer patients to establish biomarkers predictive of drug or drug combination responses. (bioconductor.org)
- Drugs reported in NAMCS and NHAMCS are coded twice: first "as entered" on the survey data collection form, using an NCHS-assigned 5-digit code, and second using a corresponding 6-digit generic-equivalent code based on the Multum classification. (cdc.gov)
- Please note that the primary purpose of this system is to facilitate the identification of drug codes used in NAMCS and NHAMCS by data users. (cdc.gov)
Classification1
- It is important to note that the drug database as well as the Multum classification can change over time. (cdc.gov)
High2
- More than half of prescription drug manufacturers have complied, but some combination drugs with high levels of acetaminophen remain on the market. (stromlaw.com)
- This is a relatively safe drug that can be safely recommended to bodybuilding beginners for a gradual build-up of high-quality and relief mass. (redcrosslaunion.org.ph)
Affects1
- Do not drive a car or operate machinery until you know how this drug affects you. (medlineplus.gov)
Patients8
- One expert discusses the significance of newer drugs and the role they play in helping patients with relapsed or refractory disease. (curetoday.com)
- Patients with mantle cell lymphoma may have new hope in drug combinations, according to Dr. Timothy Fenske, an associate professor at the Medical College of Wisconsin. (curetoday.com)
- Fenske explained that the drug showed a 75% overall response rate in an early phase trial that included 20 or 30 patients with mantle cell lymphoma. (curetoday.com)
- The conference will also cover the topic of cross-organisational evaluation and selection of drug delivery systems (DDS) technologies and suppliers, which is crucial for ensuring the best possible outcomes for patients and the environment. (vonlanthenevents.com)
- Manufacturer states that the fixed combination of dapagliflozin, saxagliptin, and extended-release metformin hydrochloride (Qternmet XR) is intended for use only in patients currently receiving metformin. (drugs.com)
- Used in combination with metformin (separately or as fixed combination of saxagliptin and extended-release metformin), a sulfonylurea, a thiazolidinedione (e.g., a peroxisome proliferator-activated receptor- γ [PPAR- γ ] agonist), or insulin for management of type 2 diabetes mellitus in patients who do not achieve adequate glycemic control with diet, exercise, and metformin, sulfonylurea, thiazolidinedione monotherapy, and/or insulin. (drugs.com)
- The timing of when the patients took the drugs cannot be ascertained. (cdc.gov)
- Other changes will also be required in various other sections of the prescribing information to educate clinicians, patients, and caregivers about the risks of these drugs. (medlineplus.gov)
Prescription2
- These are called combination drugs , and the FDA released a statement this week that it would start cracking down on prescription drug manufacturers that put more than 325 mg of acetaminophen in their painkillers. (stromlaw.com)
- Utilizing prescription drug claims for US adults aged 19 to 64 from a commercial insurance claims database with over 9.1 million continuously enrolled adults, stimulant use was defined as adults filling one or more stimulant prescriptions in a single year. (learnteethwhitening.com)
Effect1
- Drostanolone Enanthate - 200 ZPHC Zhengzhou (masteron enanthate) is a drug with a moderate anabolic effect and weak androgenic activity. (redcrosslaunion.org.ph)
Moderate1
- A moderate risk of allergic response to this drug exists. (medscape.com)
Development2
- Led by Dr Jennifer Durrant, Global Head of Medicinal and Biologics, who worked on the BSI General Devices team for over nine years previously, the team has over 55 years' combined experience in drug development, Good Manufacturing Procedures (GMP) systems and controls, and Quality by Design (QBD). (bsigroup.com)
- While these drugs show mostly good results in other parasitic worm infections, they are unsatisfactory in Trichuris trichiura infections," said Jennifer Keiser, Head of the Helminth Drug Development unit at Swiss TPH. (swisstph.ch)
Survival1
- The 10-month progression free survival rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone. (ynhh.org)
Found2
Blood2
- The level of a drug in the blood or other body fluid or tissue. (aidsmap.com)
- group 2 of these imidazole drugs on the control of received 25 mg/kg Cimetidine and 5 blood glucose level by glyburide, using mg/kg glyburide, while group 3 received animal model. (who.int)
Previously1
- Nor, despite promising studies in monkeys, have dual combinations previously worked in humans. (aidsmap.com)
Safety1
- The latest combination has alerted the DEA to issue a public safety alert . (womiowensboro.com)
Amounts1
- After one half-life, the concentration of a drug in the body amounts to half the starting dose of any drug to be eliminated from the body. (aidsmap.com)
Market3
- Introduced by the European Commission under the Medical Devices Regulation (MDR), Article 117 requires manufacturers placing drug-device combination products onto the market as an integral device and marketing them as a "medicinal product" to seek a Notified Body Opinion (NBOp). (bsigroup.com)
- What are the Market trends influencing the progress of the Dolutegravir and Its Combination Drug industry worldwide? (reportsinsights.com)
- The report is distributed over 15 Chapters to display the analysis of the global Dolutegravir and Its Combination Drug Market. (reportsinsights.com)
Products5
- Visit our drug-device combination products webpage for more information on seeking an NBOp from BSI. (bsigroup.com)
- The 5th Drug-Device Combinations & Sustainability Conference is a premier event that will bring together experts from the drug delivery field to discuss the latest developments and challenges in the regulatory environment for drug-device combinations and sustainability of products. (vonlanthenevents.com)
- This conference will provide an excellent opportunity for attendees to gain a deeper understanding of the current situation in the field of drug-device combinations and sustainability of products, and to hear from leading experts in the industry. (vonlanthenevents.com)
- Additionally, the conference will include discussions on the regulatory environment for drug-device combinations, including paperless submission requirements, legislation, and the introduction of new products. (vonlanthenevents.com)
- It offers a great opportunity to expand your knowledge and network with other professionals in the industry, and to learn about cutting-edge solutions for making combination products more sustainable. (vonlanthenevents.com)